Oncotarget

Research Papers:

A liquid fraction of extracellular matrix inhibits glioma cell viability in vitro and in vivo

Mark H. Murdock, George S. Hussey, Jordan T. Chang, Ryan C. Hill, David G. Nascari, Aparna V. Rao, Kirk C. Hansen, Lesley M. Foley, T. Kevin Hitchens, Nduka M. Amankulor and Stephen F. Badylak _

Metrics: PDF 506 views  |   Full Text 2364 views  |   ?  


Abstract

Mark H. Murdock1,2, George S. Hussey1,2, Jordan T. Chang2, Ryan C. Hill3, David G. Nascari1,2, Aparna V. Rao5, Kirk C. Hansen3, Lesley M. Foley4, T. Kevin Hitchens4,5, Nduka M. Amankulor6 and Stephen F. Badylak1,2

1 Department of Surgery, University of Pittsburgh, Pittsburgh, PA, USA

2 McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA, USA

3 Department of Biochemistry and Molecular Genetics, University of Colorado Denver, Aurora, CO, USA

4 Animal Imaging Center, School of Medicine, University of Pittsburgh, Pittsburgh, PA, USA

5 Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA, USA

6 Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, PA, USA

Correspondence to:

Stephen F. Badylak, email: badylaks@upmc.edu

Keywords: extracellular matrix; brain cancer; glioma treatment; dynamic reciprocity; tissue organization field theory

Received: September 14, 2021     Accepted: February 07, 2022     Published: February 21, 2022

Copyright: © 2022 Murdock et al. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

ABSTRACT

Suppressive effects of extracellular matrix (ECM) upon various cancers have been reported. Glioblastoma multiforme has poor prognosis and new therapies are desired. This work investigated the effects of a saline-soluble fraction of urinary bladder ECM (ECM-SF) upon glioma cells. Viability at 24 hours in 1, 5, or 10 mg/mL ECM-SF-spiked media was evaluated in primary glioma cells (0319, 1015, 1119), glioma cell lines (A172, T98G, U87MG, C6), and brain cell lines (HCN-2, HMC3). Viability universally decreased at 5 and 10 mg/mL with U87MG, HCN-2, and HCM3 being least sensitive. Apoptosis in 0319 and 1119 cells was confirmed via NucView 488. Bi-weekly intravenous injection of ECM-SF (120 mg/kg) for 10 weeks in Sprague-Dawley rats did not affect weight, temperature, complete blood count, or multi-organ histology (N = 5). Intratumoral injection of ECM-SF (10 uL of 30 mg/mL) at weeks 2–4 post C6 inoculation in Wistar rats increased median survival from 24.5 to 51 days (hazard ratio for death 0.22) and decreased average tumor volume at time of death from 349 mm3 to 90 mm3 over 10 weeks (N = 6). Mass spectrometry identified 2,562 protein species in ECM-SF, parent ECM, and originating tissue. These results demonstrate the suppressive effects of ECM on glioma and warrant further study.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 28203